This Chronic Skin Condition May Be Improved by Ozempic

Semaglutide medications such as Ozempic and Wegovy are known to help with weight management and blood sugar regulation. However, a new study suggests that they may also be effective for treating a common skin condition associated with obesity.

Hidradenitis suppurativa is a long-lasting inflammatory skin condition that affects up to 2% of the U.S. population. It is characterized by painful bumps, abscesses, skin tunnels, and thick scars that mainly appear in areas where the skin rubs together, such as the underarms and groin.

The study, which has not been peer-reviewed, was presented at the European Academy of Dermatology and Venereology Congress 2024. It is the first to explore the use of semaglutide for treating HS, as noted by the researchers in a press release.

Lead researcher Daniel Lyons, MD, from St. Vincent’s University Hospital in Dublin, Ireland, stated, “Our findings suggest that semaglutide, even at modest doses, can offer substantial benefits in managing HS. While the drug’s role in promoting weight loss is well-established, what’s particularly exciting is its potential to also reduce the frequency of HS flare-ups.”

However, larger randomized controlled trials are needed to validate these findings, according to Lyons.

For the study, Lyons and his colleagues examined 30 patients with hidradenitis suppurativa and obesity, a significant risk factor for HS. The average age of the participants was 42, with 27 being women.

The participants received a weekly semaglutide injection at an average dose of 0.8 milligrams for about 8.2 months. The researchers monitored changes in various areas, including body mass index (BMI), weight, frequency of HS flare-ups, biochemical markers like glucose and hemoglobin A1C, pain levels before and after starting the medication, and quality of life using the Dermatology Life Quality Index (DLQI).

Analysis of the data collected between June 2020 and March 2023 showed that patients had fewer HS flare-ups after starting semaglutide, with a reduction in the frequency of episodes from once every 8.5 weeks to once every 12 weeks. Quality of life also seemed to improve based on average DLQI scores.

The average BMI decreased from 43.1 to 41.5, and the average weight dropped from around 259 pounds to 246 pounds, with a third of patients losing 22 pounds or more during treatment. Hemoglobin A1c levels improved from 39.3 to 36.6, indicating better blood sugar control.

While these findings are promising, limitations should be considered, as mentioned by Alhusayen. The lack of peer-review and a control group make it challenging to determine if the improvements seen in patients were due to the medication or natural fluctuations in their condition.

Additional research is necessary to further explore different medication doses and various levels of HS severity, as noted by dermatologist Jennifer Gordon, MD from Westlake Dermatology in Austin, Texas.

Semaglutide medications like Ozempic and Wegovy may help manage HS primarily by promoting weight loss, Alhusayen explained. Obesity, being a major risk factor for HS, losing weight can reduce skin friction and systemic inflammation, thus improving HS symptoms.

GLP-1 medications can also influence HS in other ways, Gordon added. It is not surprising that these medications may help with HS from a weight loss perspective, but the metabolic changes they induce may also play a role in HS lesion development and severity.

Despite the availability of FDA-approved topical and oral antibiotics for HS treatment, Gordon suggested discussing with a dermatologist whether semaglutide medications might improve the condition. However, providers may not be comfortable prescribing the drug for that purpose until further research is available.

If you have other health issues that semaglutide can treat, Gordon mentioned that the drug could potentially address those conditions while also reducing symptoms of HS on multiple levels.

DeFi Daily News

A Closer Look at the Research

The study by Dr. Daniel Lyons and his team explored the use of semaglutide medications for treating hidradenitis suppurativa (HS) in patients with obesity. The results showed promising improvements in managing HS symptoms, weight loss, and blood sugar control. Larger clinical trials are needed to further validate these findings.

Why Might Semaglutide Help with HS?

Semaglutide medications like Ozempic and Wegovy may benefit patients with HS by promoting weight loss, which can reduce skin friction and inflammation, leading to improvements in HS symptoms. Additionally, the metabolic changes induced by GLP-1 medications may play a role in managing HS lesions.

HS Treatment Options

While there are FDA-approved treatments for HS, such as antibiotics, exploring the potential of using semaglutide medications for HS should be discussed with a dermatologist. Further research is needed to determine the efficacy of these medications specifically for HS treatment.

Conclusion

The study highlights the potential benefits of using semaglutide medications for treating hidradenitis suppurativa in patients with obesity. While the findings are promising, more research is required to establish the effectiveness of these medications for HS treatment.

FAQs

1. Are semaglutide medications FDA-approved for treating HS?

No, semaglutide medications are not currently FDA-approved for treating HS. Further research and clinical trials are needed to determine their efficacy for this specific condition.

2. What are the potential benefits of using semaglutide for HS?

Semaglutide medications may help manage HS by promoting weight loss and improving metabolic parameters, which can lead to a reduction in HS flare-ups and symptoms.

3. Should patients with HS consider using semaglutide medications?

Patients with HS should consult with their healthcare provider, typically a dermatologist, to discuss the potential benefits and risks of using semaglutide medications for their condition.